United in Action to Accelerate Cures for Patients with AML
Friday, Jan. 31, 2025
12 noon EST/9 am PST
via Zoom
Register to learn more.
Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.
Hear from LLS TAP staff and biotech partners who are united to accelerate cures for patients with AML.
Agenda:
Introduction
Moderated discussion with LLS staff and TAP company partners:
Lawrence Mayer, PhD – Celator Pharmaceuticals
Ashley Yocum, PhD – LLS Beat AML
Ann Collins, PA – LLS PedAL
Stephan Braun, MD, PhD – ImCheck Therapeutics
Q&A
How is LLS leading the way in AML research?
More than 20% of the biomedical research funded by LLS is aimed at finding cures and improving quality of life for patients with AML—that’s $75 million!
Beat AML Master Clinical Trial - continues to grow by testing precision medicine for adults with AML, exploring ways to reduce side effects and improve patients’ quality of life and making clinical trials more patient friendly